SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-10

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from STS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer

NCT02581670

Breast Cancer Metastasis to Liver Metastasis to Lung

UNKNOWN NA

SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions

NCT04455438

Non Small Cell Lung Cancer Lung Metastases

RECRUITING NA

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

NCT02581384

Ewing Sarcoma Rhabdomyosarcoma Wilms Tumor +8 more

TERMINATED PHASE1/PHASE2

Prospecitve Observational Study on a Risk Adaptive Scheme for SBRT for Thoracic Nodes Metastases

NCT02970955

Thoracic Nodes Metastases

COMPLETED

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

NCT02975609

NSCLC

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators started to treat PM oligometastatic patients with Stereotactic Body Radiotherapy.

The investigators objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from soft-tissue sarcomas. Overall and disease free survival will be evaluated as secondary endpoints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastasis From Malignant Tumor of Soft Tissues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung metastasis from soft-tissue sarcoma

Lung metastases from soft-tissue sarcoma

Lung metastasis from soft-tissue sarcoma

Intervention Type RADIATION

Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung metastasis from soft-tissue sarcoma

Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 anni -85 years
* PS according to ECOG 0-2
* Histopathologically confirmation of soft tissue sarcoma
* Metastatic lung lesion less than 4
* Controlled primary tumor and other metastatic lesions
* Metastatic lesion less than 5 such as the definition of oligometastatic patients
* Written informed consent
* Contraindication to surgical resection
* Estimated survival ≥ 3 months
* Absence of progressive disease longer than 6 months
* No chemotherapy was given for at least 3 months after SBRT
* Maximum diameter ≤ 5 cm

Exclusion Criteria

* Prior thorax radiation therapy
* Age \> 85 years
* PS according to ECOG \>2
* Pregnant women
* Maximum diameter ≥ 5.1 cm
* Total volume of lung lesion greater than 1/3 of the whole pulmonary parenchima

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes